博瑞醫藥(688166.SH):子公司博瑞香港擬對博瑞印尼增資330萬美元
格隆匯4月21日丨博瑞醫藥(688166.SH)公佈,公司一直從事高技術壁壘的醫藥中間體、原料藥和製劑產品的生產並積極參與國際競爭,為保持對國際市場的深度開發並與國外先進製藥公司開展合作,輻射東南亞及“一帶一路”市場,公司於2018年11月投資105萬美元,持有博瑞印尼35%的股權。
為了進一步鞏固公司對國際市場的戰略佈局,公司的全資子公司博瑞香港擬以自有資金對參股公司博瑞印尼增資330萬美元,增資後持股比例為48.3%,從而對博瑞印尼實現控制將其納入合併報表範圍。
本次增資前,公司通過博瑞香港持有博瑞印尼35%的股權,博瑞印尼為公司之聯營企業,公司於2020年4月離任監事張麗任博瑞印尼高級管理人員,根據《上海證券交易所科創板股票上市規則》第15.1(十四)條的相關規定,認定博瑞印尼為公司關聯法人。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.